Summary & Overview
HCPCS G0341: Percutaneous Islet Cell Transplant, Portal Vein Infusion
HCPCS Level II code G0341 represents percutaneous islet cell transplant, encompassing portal vein catheterization and infusion of donor islet cells. This specialized interventional procedure is used in select patients with severe insulin-dependent diabetes and has implications for transplant centers, payers, and specialty providers. Nationally, tracking use and coverage of G0341 matters for access to advanced cellular therapies and for aligning payment policies with clinical practice.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing considerations, and clinical context relevant to transplant and interventional radiology services.
Readers will find concise benchmarks and policy-relevant summaries, clinical context for when the procedure is performed, and notes on typical sites of service. Where payer-specific data or additional details are not available in the input, the publication will note that those items are not provided. The content is intended to inform billing professionals, transplant program administrators, and policy analysts about the role and classification of HCPCS Level II code G0341 in national practice.
Billing Code Overview
HCPCS Level II code G0341 describes percutaneous islet cell transplant, a procedure that includes portal vein catheterization and infusion of islet cells. The service involves accessing the portal venous system percutaneously and infusing donor islet cells into the liver to engraft and produce insulin.
-
Service type: Percutaneous interventional transplant procedure
-
Typical site of service: Hospital or ambulatory surgical center with interventional radiology or transplant capability
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with autoimmune type 1 diabetes mellitus and labile glycemic control despite optimized insulin therapy and continuous glucose monitoring is evaluated for islet cell transplantation. After multidisciplinary assessment including endocrinology, transplant surgery, and interventional radiology, the patient is scheduled for a percutaneous islet cell transplant. On procedure day the patient is admitted to an interventional radiology or hybrid operating suite. Under moderate sedation or general anesthesia, interventional radiology obtains percutaneous access to the portal venous system—commonly via the right internal jugular vein or transhepatic portal access—performs portal vein catheterization under fluoroscopic and ultrasound guidance, and infuses isolated donor islet cells into the portal circulation. Post-infusion portal venography confirms distribution and assesses for thrombosis. The patient is observed in a post-anesthesia care area then transferred to a monitored bed for serial vital signs, liver function tests, and anticoagulation management as indicated. Follow-up includes endocrinology visits to assess graft function, C-peptide, immunosuppression management, and surveillance for complications such as portal vein thrombosis or bleeding.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard Professional/Technical billing indicator | Use when no specific modifier is required and payer expects default code level. |